...
首页> 外文期刊>Toxicology and Applied Pharmacology >CYP4A/CYP2C modulation of the interaction of calcium channel blockers with cyclosporine on EDHF-mediated renal vasodilations in rats
【24h】

CYP4A/CYP2C modulation of the interaction of calcium channel blockers with cyclosporine on EDHF-mediated renal vasodilations in rats

机译:CYP4A / CYP2C调节钙通道阻断剂与环孢菌素对大鼠EDHF介导的肾血管舒张相互作用的调节

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract The endothelium-derived hyperpolarizing factor (EDHF) serves as a back-up mechanism that compensates for reduced nitric oxide (NO)/prostanoids bioavailability. Here we investigated whether (i) under conditions of vascular endothelium dysfunction, the immunosuppressant drug cyclosporine (CSA) upregulates EDHF-dependent renal vasodilations through altering CYP4A/CYP2C signaling, and (ii) calcium channel blockers modulate the CSA/EDHF/CYP interaction. Rats were treated with CSA, verapamil, nifedipine, or their combinations for 7days. Blood pressure (BP) was measured by tail-cuff plethysmography . Kidneys were then isolated, perfused with physiological solution containing L-NAME (NOS inhibitor) and diclofenac (cyclooxygenase inhibitor, DIC), and preconstricted with phenylephrine. CSA (25mgkg ?1 day ?1 for 7days) increased BP and augmented carbachol renal vasodilations. The co-treatment with verapamil (2mgkg ?1 day ?1 ) or nifedipine (3mgkg ?1 day ?1 ) abolished CSA hypertension and conversely affected carbachol vasodilations (increases vs. decreases). Infusion of MSPPOH (epoxyeicosatrienoic acids, EETs, inhibitor) reduced carbachol vasodilations in kidneys of all rat groups, suggesting the importance of EETs in these responses. By contrast, 20-Hydroxyeicosatetraenoic Acid (20-HETE) inhibition by HET0016 increased carbachol vasodilations in control rats, an effect that disappeared by CSA treatment, and reappeared in rats treated with CSA/verapamil or CSA/nifedipine. Renal protein expression of CYP2C and CYP4A as well as their vasoactive products (EETs/20-HETE) were increased in CSA-treated rats. Whereas the CYP2C/EETs effects of CSA were abolished by verapamil and intensified by nifedipine, the CYP4A/20-HETE effects were reduced by either CCB. Overall, nifedipine and verapamil blunts CSA hypertension but variably affected concomitantly enhanced EDHF-dependent renal vasodilations and alterations in CYP2C/CYP4A signaling. Highlights ? CSA enhances EDHF-mediated renal vasodilation. ? CSA increases renal CYP4A/CYP2C expressions and 20-HETE/EETs levels. ? Verapamil and nifedipine differently influences CSA/EDHF interaction.
机译:摘要内皮衍生的超极化因子(EDHF)用作备用机制,其补偿了减少的一氧化氮(NO)/前列腺素生物利用度。在这里,我们研究了(i)是否在血管内皮功能障碍的条件下,免疫抑制药物环孢菌素(CSA)通过改变CYP4A / CYP2C信号传导来提高EDHF依赖性肾血管缩小,并且(II)钙通道阻滞剂调节CSA / EDHF / CYP相互作用。大鼠用CSA,Verapamil,NifeDipine或7天的组合治疗。血压(BP)通过尾袖体积描记法测量。然后将肾脏分离,灌注含有L-名称(NOS抑制剂)和双氯芬酸(环氧氧酶抑制剂,DIC)的生理溶液,并用苯酚肾上腺素预先预期。 CSA(25mgkg?1天?1持续7天)增加了BP和增强的卡巴球肾血管稀释。与维拉帕米(2mgkg?1天?1)或硝苯地平(3mgkg?1天?1)的共同治疗废除了CSA高血压,并反映了受影响的卡巴肠血管血管(增加与降低)。输注MSPPOH(环氧二亚硅硅酸,EETS,抑制剂)降低了所有大鼠肾脏的肾脏血管舒张,表明EETS在这些反应中的重要性。相比之下,HET0016的20-羟基辛辛醚酸(20-HETE)抑制增加了对照大鼠的卡巴肠血管舒张,其效果消失了CSA治疗,并在用CSA / Verapamil或CSA / NiFemipine处理的大鼠中重新出血。 CYP2C和CYP4A的肾蛋白表达以及其血管活性产物(EETS / 20-HETE)在CSA处理的大鼠中增加。虽然CYP2C / EETS通过维拉帕米废除CSA的影响并被NiFemipine加剧,CYP4A / 20-HETE效应通过CCB减少。总体而言,NifeDipine和Verapamil Blunts CSA高血压,但可变地影响Cyp2C / Cyp4a信号传导的EDHF依赖性肾血管和改变。强调 ? CSA增强EDHF介导的肾血管舒张。还CSA增加肾CYP4A / CYP2C表达和20-HETE / EETS水平。还维拉帕米和硝苯地平不同地影响CSA / EDHF交互。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号